Survival, PROs Favor Cemiplimab Plus Chemotherapy vs Chemotherapy Alone in Advanced NSCLC
December 4th 2023For patients with advanced non–small cell lung cancer (NSCLC), regardless of PD-L1 status, cemiplimab plus chemotherapy had favorable survival benefits and patient-reported outcomes over chemotherapy alone.
Read More
Amivantamab Plus Lazertinib Improved PFS for EGFR-Mutated Advanced NSCLC
October 23rd 2023MARIPOSA demonstrated the combination reduced risk of progression or death by 30% compared with osimertinib. MARIPOSA-2 found amivantamab plus chemotherapy and amivantamab plus chemotherapy and lazertinib also improved progression-free survival (PFS) over chemotherapy after progression on osimertinib.
Read More
Dr Thomas Powles Discusses Impact of EV+P Therapy on Urothelial Carcinoma Treatment
October 22nd 2023Thomas Powles, MD, MBBS, MRCP, from Barts Cancer Centre, shares insights from the EV-302/KEYNOTE-A39 trial and its implications for the future of enfortumab vedotin and pembrolizumab (EV+P) combination therapy for urothelial carcinoma.
Read More
Trastuzumab Deruxtecan Demonstrates Efficacy Reducing Brain Metastases in HER2m NSCLC
October 22nd 2023Regardless of presence of brain metastases, patients with HER2-mutant (HER2m) non–small cell lung cancer (NSCLC) showed systemic responses to trastuzumab deruxtecan. In addition, the therapy showed intracranial efficacy to reduce the size of brain metastases.
Read More
Adding Adjuvant Nivolumab Builds on Standard of Care for Resectable NSCLC
October 22nd 2023The results of CheckMate 77T showcase the improved event-free survival for patients with resectable non–small cell lung cancer who receive nivolumab in both the neoadjuvant and adjuvant setting and may have practice-changing implications.
Read More
Overcoming the Efficacy-Effectiveness Gap in Cancer Therapy Research
October 21st 2023With stringent criteria, randomized controlled trials are the cornerstone of cancer intervention research, but the result is they do not represent the majority of patients, which leads to a gap between the efficacy seen in trials and the effectiveness in the real-world setting.
Read More
Dr Kevin Kalinsky Shares Real-World Data on Effects of Sacituzumab Govitecan-hziy in TNBC
October 21st 2023Kevin Kalinsky, MD, MS, of Glenn Family Breast Center, gives insight into the real-world data supporting the use of sacituzumab govitecan-hziy in the treatment of triple-negative breast cancer (TNBC).
Read More
Frontline Pembrolizumab Plus Trastuzumab/Chemotherapy Improves PFS in HER2+ Gastric/GEJ Cancer
October 20th 2023Adding pembrolizumab to combination of trastuzumab and chemotherapy improved progression-free survival vs placebo plus trastuzumab and chemotherapy in the first-line treatment of patients with metastatic HER2-positive gastric or gastroesophageal junction (GEJ) cancer.
Read More